Analysis of the molecular targets and mechanism of action of sparsentan

Sparsentan is a new dual receptor antagonist that targets both endothelin receptor A (ETA) and angiotensin II receptor (AT1R). This dual targeting mechanism makes it potentially advantageous in the treatment of kidney diseases, especially primary or secondary IgA nephropathy and FSGS (focal segmental glomerulosclerosis). By inhibiting both angiotensin II and endothelin signaling pathways, spaxantane has a synergistic effect in reducing proteinuria and protecting renal function.

In terms of angiotensinII receptor inhibition, sparsentan protects the glomerular filtration barrier by blocking AT1R, inhibiting vasoconstriction, reducing glomerular hyperfiltration and the increase in glomerular pressure, while inhibiting pro-inflammatory and pro-fibrotic signals. This mechanism is similar to traditional ARBs (angiotensin receptor antagonists), but combined with the dual mechanism of sparsentan, it enhances the proteinuria-lowering effect.

In terms of endothelin receptor antagonism, sparsentan mainly inhibits ETA receptors and reduces endothelin-mediated vasoconstriction, inflammatory response and glomerular cell proliferation. ETAThe receptor plays an important role in glomerular damage, and excessive activation can lead to glomerulosclerosis and aggravation of proteinuria. By inhibiting ETA, sparsentan can improve the glomerular microenvironment and reduce glomerular structural damage, thereby achieving renal protection.

The dual mechanism enables sparsentane to show significant potential in reducing proteinuria, delaying the decline of renal function and improving glomerular structure. Clinical trials have shown that sparsentane can significantly reduce proteinuria in patients with FSGS and IgA kidney disease compared with simple ARB or ACE inhibitors, while being well tolerated. Its unique molecular targets and mechanism of action provide new treatment strategies and clinical hope for patients with chronic kidney disease.

Reference materials:https://www.drugs.com/